Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2017, Article ID 2414878, 12 pages
https://doi.org/10.1155/2017/2414878
Research Article

Mathematical Simulation of Transport Kinetics of Tumor-Imaging Radiopharmaceutical 99mTc-MIBI

1Institute for Safety Problems of NPP, The National Academy of Sciences of Ukraine, Lisogirskaya Str. 12, Kyiv, Ukraine
2National Medical University of O.O. Bogomolets, Pr. Peremogi 34, Kyiv, Ukraine

Correspondence should be addressed to O. N. Shevtsova; moc.liamg@avostvehsko

Received 18 March 2017; Accepted 9 May 2017; Published 15 June 2017

Academic Editor: Kazuhisa Nishizawa

Copyright © 2017 O. N. Shevtsova and V. K. Shevtsova. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Khakhaly, J. Maublant, and S. Goldsmith, Eds., Nuclear Oncology: Diagnostic and Therapy, Lippincott Williams & Wilkins, Philadelphia, pa, USA, 2001.
  2. L. Mansi, P. F. Rambaldi, E. Procaccini et al., “Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases,” European Journal of Nuclear Medicine, vol. 23, no. 8, pp. 932–939, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. B. E. Hillner, “Decision analysis: MIBI imaging of nonpalpable breast abnormalities,” Journal of Nuclear Medicine, vol. 38, no. 11, pp. 1772–1778, 1997. View at Google Scholar · View at Scopus
  4. A. M. Al-Shammari, A. H. Elgazzar, and R. A. Ashkanami, “Tc99m-MIBI whole body scan: a potentially useful technique for evaluating metabolic bone disease,” World Journal of Nuclear Medicine, vol. 12, no. 1, pp. 8–13, 2013. View at Publisher · View at Google Scholar
  5. J. A. Ponto, “Mechanisms of radiopharmaceutical localization,” UNM College of Pharmacy, vol. 16, no. 4, 2012. View at Google Scholar
  6. V. Y. Kundin, “Characteristic of main radiopharmaceuticals for kidney investigation: modern state and further perspectives,” Ukrainian Radiological Journal, vol. 1, pp. 79–87, 2004. View at Google Scholar
  7. K. Schwochau, Technetium: Chemistry and Radiopharmaceutical Applications, Wiley-VCH Verlag GmbH, Weinheim, Germany, 2000. View at Publisher · View at Google Scholar
  8. Y. B. Lishmanov and V. I. Chernov, Eds., Radionuclide Diagnostic, Tomsk: STT, Tomsk, Russia, 2004.
  9. M. Piga, P. Bolasco, L. Satta et al., “Double-phase parathyroid technetium-99m-MIBI scintigraphy to identify functional autonomy in secondary hyperparathyroidism,” The Journal of Nuclear Medicine, vol. 37, pp. 565–569, 1996. View at Google Scholar
  10. I. Ak, J. A. K. Blokland, E. K. J. Pauwels, and M. P. M. Stokkel, “The clinical value of 18F-FDG detection with a dual-head coincidence camera: A review,” European Journal of Nuclear Medicine, vol. 28, no. 6, pp. 763–778, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-B. Ong and D. J. Hausenloy, “Mitochondrial morphology and cardiovascular disease,” Cardiovascular Research, vol. 88, no. 1, pp. 16–29, 2010. View at Publisher · View at Google Scholar
  12. A. Lockhart, L. Tirona, and R. Kim, “Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy,” Molecular Cancer Therapeutics, vol. 2, pp. 685–698, 2003. View at Google Scholar
  13. S. G. Aller, J. Yu, A. Ward et al., “Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding,” Science, vol. 323, no. 5922, pp. 1718–1722, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Sailaja, D. Surekha, D. N. Rao, D. R. Rao, and S. Vishnupriya, “ABCB1 (MDR1, P-Glycoprotein) C3435T Gene Polymorphism and its Possible Assisiation with Chronic Myeloid Leukemia Prognosis,” Current Trends in Biotechnology and Pharmacy, vol. 2, pp. 514–522, 2008. View at Google Scholar
  15. F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham, “Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7735–7738, 1987. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Mizutani, M. Masuda, E. Nakai et al., “Genuine functions of P-glycoprotein (ABCB1),” Current Drug Metabolism, vol. 9, no. 2, pp. 167–174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Kannan, C. John, S. S. Zoghbi et al., “Imaging the function of P-glycoprotein with radiotracers: Pharmacokinetics and in vivo applications,” Clinical Pharmacology and Therapeutics, vol. 86, no. 4, pp. 368–377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, “Targeting multidrug resistance in cancer,” Nature Reviews Drug Discovery, vol. 5, no. 3, pp. 219–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Ghibellini, L. Vasist, W. Heizer, R. Kowalsky, and R. Brouner, “Quantitation of Tc-99m-sestamibi bibliary exretion in humans,” Clinical Pharmacology & Therapeutics, vol. 79, article 19, 2005. View at Google Scholar
  20. I. Cascorbi, T. Gerloff, A. Johne et al., “Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects,” Clinical Pharmacology & Therapeutics, vol. 69, no. 3, pp. 169–174, 2001. View at Publisher · View at Google Scholar
  21. M. F. Fromm, “Genetically determined differences in P-glycoprotein function: implications for disease risk,” Toxicology, vol. 181-182, pp. 299–303, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. K. L. Miller, K. T. Kelsey, J. K. Wiencke et al., “The C3435T polymorphism of MDR1 and susceptibility to adult glioma,” Neuroepidemiology, vol. 25, no. 2, pp. 85–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Jamroziak, W. Młynarski, E. Balcerczak et al., “Functional C3435T polymorphism of MDR1 gene: An impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia,” European Journal of Haematology, vol. 72, no. 5, pp. 314–321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Sigesmund, U. Brinkmann, E. Schaffler et al., “Association of the P-glycoprotein transporter MDR1 C3435T polymorphism with the susceptibility to renal epithelial tumors,” Journal of the American Society of Nephrology, vol. 13, pp. 1847–1854, 2002. View at Google Scholar
  25. S. Turgut, A. Yaren, R. Kursunluoglu, and G. Turgut, “MDR1 C3435T Polymorphism in Patients with Breast Cancer,” Archives of Medical Research, vol. 38, no. 5, pp. 539–544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. J. Koziolek, R. Riess, H. Geiger, F. Thévenod, and I. A. Hauser, “Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients,” Kidney International, vol. 60, no. 1, pp. 156–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Wong, S. Evans, L. P. Rivory et al., “Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer,” Clinical Pharmacology and Therapeutics, vol. 77, no. 1, pp. 33–42, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Piwnica-Worms, M. L. Chiu, M. Budding, J. F. Kronauge, R. A. Kramer, and J. M. Croop, “Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex,” Cancer Research, vol. 53, no. 5, pp. 977–984, 1993. View at Google Scholar · View at Scopus
  29. S. Dizdarevic and A. M. Peters, “Imaging of multidrug resistance in cancer,” Cancer Imaging, vol. 11, no. 1, pp. 1–8, 2011. View at Publisher · View at Google Scholar
  30. S. Dizdarevic and A. Peters, “Radionuclide imaging of multidrug resistance,” in Nuclear Oncology, C. Aktolun and C. Goldsmith, Eds., pp. 530–535, Wolters Kluwer Health, Philadelphia, Pa, USA, 2nd edition, 2015. View at Google Scholar
  31. C. C. Chen, B. Meadows, J. Regis et al., “Detection of in-vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-sestamibi,” Clinical Cancer Research, vol. 3, no. 4, pp. 545–552, 1997. View at Google Scholar · View at Scopus
  32. Y.-S. Chen, W.-H. A. Wang, T. Chan, S.-S. Sun, and A. Kao, “A review of the cost-effectiveness of Tc-99m sestamibi scintimammography in diagnosis of breast cancer in Taiwanese women with indeterminate mammographically dense breast,” Surgical Oncology, vol. 11, no. 3, pp. 151–155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Mubashar, K. J. Harrington, K. S. Chaudhary, E.-N. Lalani, G. W. Stamp, and A. M. Peters, “Erratum: Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in p-glycoprotein-expressing breast and head and neck cancer cell lines,” Acta Oncologica, vol. 43, no. 6, article 606, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Piwnica-Worms, J. F. Kronauge, and M. L. Chiu, “Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells,” Journal of Nuclear Medicine, vol. 32, no. 10, pp. 1992–1999, 1991. View at Google Scholar · View at Scopus
  35. J. Maublant and J. Baggott, “Technetium-99m-sestamibi cellular uptake: passive or secondary active transport?” Journal of Nuclear Medicine, vol. 38, no. 7, article 1170, 1997. View at Google Scholar · View at Scopus
  36. S. Matsuo, K. Nakajima, and S. Kinuya, “Evaluation of cardiac mitochondrial function by a nuclear imaging technique using technetium-99m MIBI uptake kinetics,” Asia Oceania Journal of Nuclear Medicine and Biology, vol. 1, no. 1, pp. 39–43, 2013. View at Google Scholar
  37. T. M. Delvin, “Biological membranes: structure and membrane transport,” in Textbook of Biochemistry with Clinical Correlations, T. M. Delvin, Ed., vol. 226, Wiley-Liss, New York, NY, USA, 3rd edition, 1992. View at Google Scholar
  38. D. Piwnica-Worms, J. F. Kronauge, and M. L. Chiu, “Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence,” Circulation, vol. 82, no. 5, pp. 1826–1838, 1990. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Piwnica-Worms, J. F. Kronauge, A. LeFurgey et al., “Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy,” Magnetic Resonance Imaging, vol. 12, no. 4, pp. 641–652, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Backus, D. Piwnica-Worms, D. Hockett et al., “Microprobe Analysis of Tc-MIBI in heart cells: calculation of mitochondrical membrane potential,” American Journal of Physiology, vol. 265, no. 1, pp. 178–187, 1993. View at Google Scholar
  41. B. M. Gallagher, J. S. Fowler, N. I. Gutterson et al., “Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose,” Journal of Nuclear Medicine, vol. 19, no. 10, pp. 1154–1161, 1978. View at Google Scholar · View at Scopus
  42. N. C. Gupta and M. P. Frick, “Clinical applications of positron‐emission tomography in cancer,” CA: A Cancer Journal for Clinicians, vol. 43, no. 4, pp. 235–254, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. S. C. Linn, G. Giaccone, P. J. Van Diest et al., “Prognostic relevance of P-glycoprotein expression in breast cancer,” Annals of Oncology, vol. 6, no. 7, pp. 679–685, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. S. D. Vecchio, A. Ciarmiello, L. Pace et al., “Fraction Retention of technetium-99m-Sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients,” Journal of Nuclear Medicine, vol. 38, no. 9, pp. 1348–1351, 1997. View at Google Scholar
  45. A. Ciarmiello, S. Del Vecchio, P. Silvestro et al., “Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer,” Journal of Clinical Oncology, vol. 16, no. 5, pp. 1677–1683, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Mubashar, K. J. Harrington, K. S. Chaudhary et al., “99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer,” Journal of Nuclear Medicine, vol. 43, no. 4, pp. 519–525, 2002. View at Google Scholar · View at Scopus
  47. R. Sciuto, R. Pasqualoni, S. Bergomi et al., “Prognostic value of 99mTc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy,” Journal of Nuclear Medicine, vol. 43, no. 6, pp. 745–751, 2002. View at Google Scholar · View at Scopus
  48. R. Sciuto, R. Pasqualoni, S. Bergomi et al., “Prognostic value of 99mTc-Sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients,” Journal of Nuclear Medicine, vol. 38, no. 9, pp. 1348–1351, 1997. View at Google Scholar
  49. D. O. Dzuzha, “The features of 99m-Tc(V) DMCA kinetics in metastases of medullar thyroid cancer: the possible ways of optimization of the scintigraphy at postoperative monitoring,” Ukrainian Journal of Radiology, vol. 22, no. 3, pp. 66–70, 2014. View at Google Scholar
  50. D. O. Dzuzha, D. L. Sagan, and V. V. Danilenko, “The features of kinetics 153SM-oksabifor in bone metastases of cancer of different localization at radionuclide therapy,” Ukrainian Journal of Radiology, vol. 23, no. 3, pp. 77–82, 2015. View at Google Scholar
  51. H. Watabe, Y. Ikoma, Y. Kimura, M. Naganawa, and M. Shidahara, “PET kinetic analysis—compartmental model,” Annals of Nuclear Medicine, vol. 20, no. 9, pp. 583–588, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. E. B. Hauser, “Laplace transform in tracer kinetic modeling,” in Proceedings of the International Nuclear Atlantic Conference-INAC, Associacao Brasileira De Energia Nuclear-Aben, Recife, Brazil, November 2013.
  53. A. V. Matveev and M. Y. Korneeva, “Peculiarities of radiotracer kinetic simulation at functional investigation of the hepatobiliary system,” Vestnik of Omsk University, vol. 3, pp. 42–51, 2015 (Russian). View at Google Scholar
  54. A. S. Lunev, “Mathematical simulation of transport kinetics of radiopharmaceutical 68-Ga-citrate for PET imaging of inflammation,” Nuclear Medicine, vol. 60, no. 6, pp. 42–47, 2015 (Russian). View at Google Scholar
  55. O. V. Shcherbina, “Methods of radionuclide diagnostics in patients with breast cancer,” Oncology, vol. 11, no. 4, pp. 298–301, 2009 (Russian). View at Google Scholar